CAR-T Cell Therapy

Revolutionary Immunotherapy for Blood Cancers

Engineering patient's own T cells into "anti-cancer special forces" with Chimeric Antigen Receptor technology

CAR-T Therapy

What is CAR-T Therapy?

CAR-T (Chimeric Antigen Receptor T-Cell) therapy is a breakthrough immunotherapy that uses genetic engineering to modify a patient's own T cells. T cells are collected, engineered to express chimeric antigen receptors that can precisely recognize and attack cancer cells, then expanded and infused back into the patient.

Think of it as upgrading your immune cells into "anti-cancer special forces" - a highly personalized cell therapy that harnesses the power of your own immune system to fight cancer.

Back to Therapies Contact Us

Key Advantages of CAR-T in China

China has established global leadership in CAR-T cell therapy

Cost-Effective

Significantly lower cost compared to US ($400,000-500,000 per treatment)

Faster Production

Automated cell preparation shortens production cycle dramatically

Better Safety Profile

CRS rate <5% vs 30-40% in Western countries

China's Global Leadership

China leads the world in CAR-T product development and clinical application

8
Approved CAR-T Products
(More than US)
80-90%
Remission Rate for
Blood Cancers
54.9%
Efficacy in Gastric Cancer
(Claudin18.2 target)
<5%
Cytokine Release Syndrome
Rate

Treatment Indications

  • Acute Lymphoblastic Leukemia (ALL)

    Particularly effective for relapsed/refractory B-cell ALL

  • B-Cell Non-Hodgkin Lymphoma

    High response rates in diffuse large B-cell lymphoma

  • Multiple Myeloma

    3 products approved specifically for this indication

  • Solid Tumors (Research Stage)

    Claudin18.2 CAR-T showing promise in gastric cancer

CAR-T Cells

Explore CAR-T Therapy Options

Contact us for personalized CAR-T treatment consultation

Consult Now